“Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients

Rokkam, Venkata Ram Pradeep; Vegunta, Radhakrishna; Prudhvi, Kalyan; Vegunta, Rathnamitreyee; Kotagiri, Rajesh; Boregowda, Umesha; Sridharan, Gurusaravanan Kutti

doi:10.1016/j.obmed.2020.100284

Cited by 12 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persons with obese BMIs also suffer from immune system dysfunction and chronic inflammation which may impair their ability to fight infection [ 16 , 17 ]. When COVID-19 vaccines were initially rolled out to the public, the Advisory Committee on Immunization Practices (ACIP) included obesity as a qualifier for eligibility in Phase 1c of the COVID-19 vaccine allocations [ 17 ]. However, there is hesitation due to safety concerns and alleged decreased immunologic efficacy in this population [ 18 ].…”

mentioning

confidence: 99%

Obesity implications on SARS-CoV-2 infections' prevalence, hospitalizations, critical care needs, fatalities & vaccination rates: A public health crisis

Alfaro

Autrey

Sen-Crowe

et al. 2021

Annals of Medicine and Surgery

View full text Add to dashboard Cite

mentioning

confidence: 99%

Obesity implications on SARS-CoV-2 infections' prevalence, hospitalizations, critical care needs, fatalities & vaccination rates: A public health crisis

Alfaro

Autrey

Sen-Crowe

et al. 2021

Annals of Medicine and Surgery

View full text Add to dashboard Cite

“…Further animal study is needed to understand and document DMQ-induced thrombocytosis and its short- and long-term effects. The release of inflammatory cells and cellular response to infection could be hypothetical explanations for the occurrence of secondary thrombocytosis (Rokkam and Kotagiri 2020)…”

Section: Discussionmentioning

confidence: 99%

In-Vivo and In-Vitro Toxicity Evaluation of 2,3-Dimethylquinoxaline: an Antimicrobial Found in a Traditional Herbal Medicine

Alfadil,

Alsamhan,

Ali

et al. 2024

Preprint

View full text Add to dashboard Cite

2,3-dimethylquinoxaline (DMQ) is a broad-spectrum antimicrobial phytochemical. This study aims to assess its toxicological profile. In vitro studies conducted in appropriate cell cultures, included assessment of cardiotoxicity, nephrotoxicity, and hepatotoxicity. An in vivo study was conducted in mice to determine acute oral toxicity (AOT), and subacute oral toxicity (SAOT). Acute dermal toxicity (ADT) was conducted in rats. All in-vitro toxicity studies of DMQ had negative results at concentrations ≤q100 µM except for a non-significant reduction in the ATP in human hepatocellular carcinoma cell culture. The median lethal dose of DMQ was higher than 2000 mg/kg. All animals survived the scheduled necropsy and none showed any alteration in clinical signs. Biochemistry analysis revealed a significant difference between the satellite and control groups, showing an increase in platelet counts and white blood cell counts by 99.8% and 188.8%, respectively. Histology revealed enlargement of renal corpuscles; hyperplasia of testosterone-secreting cells; and dilatation of coronaries and capillaries. The present data suggests an acceptable safety profile of DMQ in rodents except for thrombocytosis, leukocytosis, and histological changes in high doses that need further investigation.

show abstract

“…Specific attention has been paid to obese patients, who are at higher risk of severe respiratory form of COVID-19, and also at higher risk of thrombosis [54]. The potential of anti-Xa monitoring to improve lowmolecular-weight heparin effectiveness remains unknown, with little evidence to support its therapeutic range but some observational evidence in ICU patients with SARS-CoV-2 supporting further research [55,56].…”

Section: Critically-ill Inpatientsmentioning

confidence: 99%

Thromboprophylaxis strategies to improve the prognosis of COVID-19

Bertoletti

Bikdeli

Zuily

et al. 2021

Vascular Pharmacology

View full text Add to dashboard Cite

“Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients

Cited by 12 publications

References 20 publications

Obesity implications on SARS-CoV-2 infections' prevalence, hospitalizations, critical care needs, fatalities & vaccination rates: A public health crisis

Obesity implications on SARS-CoV-2 infections' prevalence, hospitalizations, critical care needs, fatalities & vaccination rates: A public health crisis

In-Vivo and In-Vitro Toxicity Evaluation of 2,3-Dimethylquinoxaline: an Antimicrobial Found in a Traditional Herbal Medicine

Thromboprophylaxis strategies to improve the prognosis of COVID-19

Contact Info

Product

Resources

About